On March 26, 2020 Oncoceutics, Inc. reported that the Chinese National Intellectual Property Administration (CNIPA) has issued a Notice of Allowance for a Composition of Matter patent for ONC201, the company’s lead development candidate, as well as for several other compounds of the imipridone family (Press release, Oncoceutics, MAR 26, 2020, View Source [SID1234558314]). This new patent, along with a Composition of Matter patent for ONC201 issued in the United States in March 2019 and an intention to grant from the European Patent Office issued in August 2019, gives Oncoceutics extensive coverage for ONC201 around the world.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oncoceutics licensed this group of patents from The Scripps Research Institute in August 2019 to expand its already broad patent coverage of ONC201 and related compounds. With these new patents, Oncoceutics has more than 20 patents for ONC201 issued globally with 10 patents for ONC201 issued by the United States Patent Office.

"We are delighted that CNIPA has recognized ONC201 and our portfolio of novel compounds, called imipridones, and is reviewing the Composition of Matter patent in China," said Martin Stogniew, Ph.D., Chief Development Officer at Oncoceutics